Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Sell
33
BIO Quote, Financials, Valuation and Earnings
Last price:
$296.26
Seasonality move
:
7.47%
Day range:
$293.94 - $308.57
52-week range:
$211.43 - $373.69
Dividend yield:
0%
P/E ratio:
27.23x
P/S ratio:
3.19x
P/B ratio:
1.19x
Volume:
227.5K
Avg. volume:
196.9K
1-year change:
-15.86%
Market cap:
$8B
Revenue:
$2.6B
EPS (TTM):
-$24.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
|
$602.4M | $2.51 | 4.07% | -91.72% | $348.00 |
|
AZTA
Azenta, Inc.
|
$149.5M | $0.16 | 4.22% | 86.12% | $43.50 |
|
BNGO
Bionano Genomics, Inc.
|
$8.4M | -$0.75 | 29.66% | -82.39% | $7.50 |
|
BRKR
Bruker Corp.
|
$799.6M | $0.41 | -0.28% | 258.65% | $54.07 |
|
HBIO
Harvard Bioscience, Inc.
|
$21.3M | -$0.01 | -2.41% | -99.56% | $2.00 |
|
KMTS
Kestra Medical Technologies Ltd.
|
$22.9M | -$0.60 | 51.57% | -24.07% | $29.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
|
$296.57 | $348.00 | $8B | 27.23x | $0.00 | 0% | 3.19x |
|
AZTA
Azenta, Inc.
|
$40.05 | $43.50 | $1.8B | -- | $0.00 | 0% | 3.09x |
|
BNGO
Bionano Genomics, Inc.
|
$1.62 | $7.50 | $16.5M | -- | $0.00 | 0% | 0.19x |
|
BRKR
Bruker Corp.
|
$50.33 | $54.07 | $7.6B | 77.08x | $0.05 | 0.4% | 2.22x |
|
HBIO
Harvard Bioscience, Inc.
|
$0.59 | $2.00 | $26.4M | -- | $0.00 | 0% | 0.30x |
|
KMTS
Kestra Medical Technologies Ltd.
|
$24.60 | $29.00 | $1.2B | -- | $0.00 | 0% | 17.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
|
17.16% | 1.381 | 18.45% | 3.62x |
|
AZTA
Azenta, Inc.
|
3.35% | 2.732 | 4.55% | 2.22x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -0.584 | 103.34% | 1.58x |
|
BRKR
Bruker Corp.
|
45.23% | 1.043 | 40.19% | 0.76x |
|
HBIO
Harvard Bioscience, Inc.
|
75.26% | 4.654 | 218.87% | 0.35x |
|
KMTS
Kestra Medical Technologies Ltd.
|
21.45% | 0.000 | 3.43% | 5.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
|
$342.8M | $66.4M | -8.14% | -9.77% | 10.17% | $89.2M |
|
AZTA
Azenta, Inc.
|
$72.3M | $2.9M | 1.39% | 1.44% | 1.85% | -$5.7M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
BRKR
Bruker Corp.
|
$399.6M | $55.2M | -0.56% | -1.2% | 6.42% | -$54.1M |
|
HBIO
Harvard Bioscience, Inc.
|
$11.2M | $245K | -68.29% | -155.33% | 1.19% | $482K |
|
KMTS
Kestra Medical Technologies Ltd.
|
$11.4M | -$31.8M | -77.65% | -105.99% | -140.73% | -$25.8M |
Bio-Rad Laboratories, Inc. vs. Competitors
-
Which has Higher Returns BIO or AZTA?
Azenta, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of 32.45%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Azenta, Inc.'s return on equity of 1.44%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B AZTAAzenta, Inc.45.4% $1.11 $1.8B -
What do Analysts Say About BIO or AZTA?
Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 17.34%. On the other hand Azenta, Inc. has an analysts' consensus of $43.50 which suggests that it could grow by 8.61%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Azenta, Inc., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Azenta, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories, Inc.2 3 0 AZTAAzenta, Inc.2 3 0 -
Is BIO or AZTA More Risky?
Bio-Rad Laboratories, Inc. has a beta of 1.177, which suggesting that the stock is 17.748% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.316, suggesting its more volatile than the S&P 500 by 31.601%.
-
Which is a Better Dividend Stock BIO or AZTA?
Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or AZTA?
Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Azenta, Inc. quarterly revenues of $159.2M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Azenta, Inc.'s net income of $51.7M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.19x versus 3.09x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories, Inc.3.19x 27.23x $653M -$341.9M AZTAAzenta, Inc.3.09x -- $159.2M $51.7M
-
Which has Higher Returns BIO or BNGO?
Bionano Genomics, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -115.42%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About BIO or BNGO?
Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 17.34%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 362.96%. Given that Bionano Genomics, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Bio-Rad Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories, Inc.2 3 0 BNGOBionano Genomics, Inc.1 0 0 -
Is BIO or BNGO More Risky?
Bio-Rad Laboratories, Inc. has a beta of 1.177, which suggesting that the stock is 17.748% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.141, suggesting its more volatile than the S&P 500 by 14.145%.
-
Which is a Better Dividend Stock BIO or BNGO?
Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or BNGO?
Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.19x versus 0.19x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories, Inc.3.19x 27.23x $653M -$341.9M BNGOBionano Genomics, Inc.0.19x -- $7.4M -$8.5M
-
Which has Higher Returns BIO or BRKR?
Bruker Corp. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -6.8%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bruker Corp.'s return on equity of -1.2%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B BRKRBruker Corp.46.44% -$0.41 $4.5B -
What do Analysts Say About BIO or BRKR?
Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 17.34%. On the other hand Bruker Corp. has an analysts' consensus of $54.07 which suggests that it could grow by 7.43%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Bruker Corp., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Bruker Corp..
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories, Inc.2 3 0 BRKRBruker Corp.7 5 1 -
Is BIO or BRKR More Risky?
Bio-Rad Laboratories, Inc. has a beta of 1.177, which suggesting that the stock is 17.748% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.
-
Which is a Better Dividend Stock BIO or BRKR?
Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.4% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or BRKR?
Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bruker Corp.'s net income of -$58.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.19x versus 2.22x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories, Inc.3.19x 27.23x $653M -$341.9M BRKRBruker Corp.2.22x 77.08x $860.5M -$58.5M
-
Which has Higher Returns BIO or HBIO?
Harvard Bioscience, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -5.98%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B HBIOHarvard Bioscience, Inc.54.23% -$0.03 $56.9M -
What do Analysts Say About BIO or HBIO?
Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 17.34%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 237.61%. Given that Harvard Bioscience, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Bio-Rad Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories, Inc.2 3 0 HBIOHarvard Bioscience, Inc.1 1 0 -
Is BIO or HBIO More Risky?
Bio-Rad Laboratories, Inc. has a beta of 1.177, which suggesting that the stock is 17.748% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.526, suggesting its more volatile than the S&P 500 by 52.562%.
-
Which is a Better Dividend Stock BIO or HBIO?
Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or HBIO?
Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.19x versus 0.30x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories, Inc.3.19x 27.23x $653M -$341.9M HBIOHarvard Bioscience, Inc.0.30x -- $20.6M -$1.2M
-
Which has Higher Returns BIO or KMTS?
Kestra Medical Technologies Ltd. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -145.29%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M -
What do Analysts Say About BIO or KMTS?
Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 17.34%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.00 which suggests that it could grow by 17.89%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Kestra Medical Technologies Ltd. is more attractive than Bio-Rad Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories, Inc.2 3 0 KMTSKestra Medical Technologies Ltd.5 1 0 -
Is BIO or KMTS More Risky?
Bio-Rad Laboratories, Inc. has a beta of 1.177, which suggesting that the stock is 17.748% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BIO or KMTS?
Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or KMTS?
Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.19x versus 17.01x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories, Inc.3.19x 27.23x $653M -$341.9M KMTSKestra Medical Technologies Ltd.17.01x -- $22.6M -$32.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Will Data Centers Be In Space?
With demand for data centers seemingly growing by the day,…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 24
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
64
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Sell
19
APGE alert for Jan 24
Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.
